Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00882583 · ClinicalTrials.gov registry record · Phase 1
A Study of Dasatinib, Cetuximab and Radiation With or Without Cisplatin in HNSCC
A Phase 1 study, sponsored by Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins.
- Terminated
- Registry status
- Phase 1
- Development phase
- 22
- Enrollment target
NCT00882583 is a Phase 1 study that was terminated before completion, run by Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins. The registered enrollment target is 22 participants.
The verdict
NCT00882583, a Phase 1 study, was terminated before completion, sponsored by Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 22 participants
- Enrollment target
Study Summary
Primary Objective for Phase I 1. To determine the maximally tolerated dose (MTD) of daily Oral dasatinib in combination with cetuximab/RT in Cohort A. 2. To determine the MTD of daily oral dasatinib in combination with cisplatin/cetuximab/RT in Cohort B
Interventions
- DRUG Cisplatin
- RADIATION Radiation Therapy
- DRUG Cetuximab
- DRUG Dasatinib
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 22 participants |
| Start Date | 2009-07 |
| Est. Completion | 2016-02 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00882583
The ClinicalTrials.gov registry entry for NCT00882583 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 22 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, which has 523 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which Cisplatin is the first listed.
NCT00882583 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00882583 about?
NCT00882583 is a clinical study titled "A Study of Dasatinib, Cetuximab and Radiation With or Without Cisplatin in HNSCC". Primary Objective for Phase I 1. To determine the maximally tolerated dose (MTD) of daily Oral dasatinib in combination with cetuximab/RT in Cohort A. 2. To determine the MTD of daily oral dasatinib in combination with cisplatin/cetuximab/RT in Cohort B
What is the current status of trial NCT00882583?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 22 participants. The study started on 2009-07. Estimated completion is 2016-02.
What interventions are being tested in trial NCT00882583?
The interventions under investigation include: Cisplatin (DRUG), Radiation Therapy (RADIATION), Cetuximab (DRUG), Dasatinib (DRUG).
Who is sponsoring clinical trial NCT00882583?
This trial is sponsored by Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, which has 523 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.